A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus

Stopped Lilly's decision to cancel this trial is due to regulatory uncertainty in China.

Conditions

• Diabetes Mellitus, Type 2

Interventions

• DRUG: Insulin Peglispro
• DRUG: Insulin Glargine

Sponsor

Eli Lilly and Company